Sante Capital Fund’s Haemonetics HAE Stock Holding History

Sante Capital Fund’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12,590	Closed	-$839K	–	65
2021 Q2	$839K	Buy	+12,590	New	+$891K	0.35%	81

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sante Capital Fund's HAE Position: Q3 2021 in Review

Sante Capital Fund sold out of Haemonetics (HAE) in Q3 2021, closing a stake of 12,590 shares — an estimated $839K sold.

Sante Capital Fund first reported a position in HAE in Q2 2021 and held it in 1 quarter. The position peaked at $839K in Q2 2021. 245 funds tracked by Wall St. Rank hold HAE as of Q3 2021.

Sante Capital Fund reported no remaining Haemonetics position as of Q3 2021 after selling out during the quarter.
Sante Capital Fund sold 12,590 Haemonetics shares in Q3 2021, an estimated $839K.
Sante Capital Fund first reported a position in Haemonetics in Q2 2021 and held it in 1 quarter.
Sante Capital Fund's Haemonetics position peaked at $839K in Q2 2021.
245 funds tracked by Wall St. Rank held Haemonetics as of Q3 2021.

Based on Sante Capital Fund's 13F filing for Q3 2021, filed 15 Nov 2021.